Latest Pharmaceuticals News

Page 44 of 73
Thorney Technologies Ltd reported a reduced net loss of $4.66 million for FY2025, improving from a $21.7 million loss the previous year, while maintaining a stable net tangible asset backing per share. The company is focused on enhancing portfolio performance and addressing the persistent discount to net tangible assets through strategic initiatives including a share buyback.
Victor Sage
Victor Sage
26 Aug 2025
Starpharma reports a significant 183% jump in FY25 revenue to $4.9 million, alongside a 31% reduction in losses and a solid cash position of $15.4 million. The biotech firm’s progress underscores growing momentum in its dendrimer technology pipeline.
Ada Torres
Ada Torres
26 Aug 2025
Neurizon Therapeutics reported a $16.6 million loss for FY2025 amid significant progress in its lead neurodegenerative therapy NUZ-001, including regulatory milestones and a global licensing deal. The company is poised to enter a pivotal ALS clinical trial pending FDA clearance.
Ada Torres
Ada Torres
26 Aug 2025
Amplia Therapeutics has successfully raised A$2.65 million through its Share Purchase Plan, exceeding expectations and bolstering funding for pivotal clinical trials of its lead drug narmafotinib.
Ada Torres
Ada Torres
26 Aug 2025
Holista Colltech has inked a binding supply and development agreement with US-based Regenerex Pharma to exclusively supply proprietary ovine collagen for advanced wound care products, targeting the lucrative US market initially with plans for global expansion.
Ada Torres
Ada Torres
26 Aug 2025
Firebrick Pharma has closed a $1.4 million placement to fund expansion of its Nasodine nasal spray in key international markets and advance new product development.
Ada Torres
Ada Torres
26 Aug 2025
Actinogen Medical reports steady progress in its Alzheimer’s and depression drug trials, backed by strong funding and strategic commercial planning. Key interim data from the pivotal XanaMIA trial is expected early next year.
Ada Torres
Ada Torres
25 Aug 2025
Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.
Ada Torres
Ada Torres
25 Aug 2025
Neuren Pharmaceuticals has initiated the first US investigational site for its pivotal Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, marking a significant milestone in addressing this rare neurodevelopmental disorder.
Ada Torres
Ada Torres
25 Aug 2025
LTR Pharma’s SPONTAN nasal spray has achieved unanimous patient satisfaction in treating erectile dysfunction after prostate surgery, signaling a promising shift in therapy preferences.
Ada Torres
Ada Torres
25 Aug 2025
Navigator Global Investments Limited (ASX, NGI) reported a robust 80% increase in net profit for FY25, driven by strong performance fees and strategic acquisitions including 1315 Capital Partners. The company also announced key board transitions as it reviews its dividend policy amid growth ambitions.
Claire Turing
Claire Turing
25 Aug 2025
Nyrada Inc. reported a sharp 25% decline in revenues alongside a 248% surge in net losses for the fiscal year ending June 2025, signaling mounting financial pressures for the pharmaceutical developer.
Ada Torres
Ada Torres
22 Aug 2025